CorMedix Inc. (CRMD) CEO Khoso Baluch on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/30/21
CorMedix Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CorMedix Inc. - CRMDPRNewsWire • 03/24/21
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30GlobeNewsWire • 03/23/21
CorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority ProgramGlobeNewsWire • 03/15/21
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical OperationsGlobeNewsWire • 03/11/21
Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to DeclineZacks Investment Research • 03/08/21
CorMedix Receives Complete Response Letter From FDA for DefenCath™ Catheter Lock SolutionGlobeNewsWire • 03/01/21
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not NeededGlobeNewsWire • 11/18/20
CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha • 11/05/20
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5GlobeNewsWire • 10/29/20
Why CorMedix Could See 300% Upside From the Defencath Central Venous Catheter24/7 Wall Street • 09/21/20